Hedge fund Sachem Head built CVS stake during second quarter
By Svea Herbst-Bayliss
NEW YORK, Aug 14 (Reuters) -Investment firm Sachem Head Capital Management built a new stake in CVS Health Corp CVS.N during the second quarter when the healthcare company's stock price dropped roughly 25%, according to a regulatory filing made on Wednesday.
The firm, run by Scott Ferguson, owned 2.45 million shares, or 0.20% of the company, on June 30, the filing showed.
A representative for Sachem Head did not comment on what the firm's plans are for the investment, which is one of the hedge fund's biggest along with ZoomInfo Technologies ZI.O and Twilio TWLO.N.
Speculation has mounted among fund managers that an activist investor may swoop in to push CVS to make changes that would boost its share price. Since January, CVS' stock price has dropped 31% while the broader market has climbed roughly 15%.
Sachem Head, which settled a proxy fight with US Foods Holding Corp two years ago, also cut back its holding in the stock by nearly 30% during the quarter.
The company remained Sachem Head's biggest U.S. investment on June 30, with a holding of 9.7 million shares, which was a 4% stake in the company. This week, Sachem Head said in a new filing that it had further cut its US Foods investment to roughly 5 million shares, a 2% stake in the company.
Investment managers are required to tell regulators how much stock they owned in U.S. companies at the end of each quarter in so-called 13F filings. While the filings are backward looking, other investors watch them closely for hints on trends, including suggestions of which companies activist investors might be targeting.
Reporting by Svea Herbst-Bayliss; editing by Miral Fahmy
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
